Search Result

Results for "

PRMT5-MTA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Methyltransferase (9) Isotope-Labeled Compounds (1)
By Research Areas:	Cancer (9)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138684

MRTX9768	Histone Methyltransferase	Cancer
MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-138684A

MRTX9768 hydrochloride	Histone Methyltransferase	Cancer
MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-139611C

Navlimetostat hydrochloride 3 Publications Verification MRTX-1719 hydrochloride	Histone Methyltransferase	Cancer
Navlimetostat hydrochloride is a potent first-in-class selective inhibitor of the *PRMT5/MTA* complex, with an IC₅₀ of less than 10 nM in PRMT5/MTA MTAP ^DEL SDMA cells .

HY-139611

Navlimetostat 3 Publications Verification MRTX-1719	Histone Methyltransferase	Cancer
Navlimetostat is a potent, orally active, selective *PRMT5•MTA* complex inhibitor, with IC₅₀ of 3.6 and 20.5 nM for *PRMT5•MTA* and *PRMT5. Navlimetostat binds to the PRMT5•MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-139611B

(S)-Navlimetostat (S)-MRTX-1719	Histone Methyltransferase	Cancer
(S)-Navlimetostat (example 16-7) is the S-enantiomer of Navlimetostat. (S)-Navlimetostat is a *PRMT5/MTA* complex inhibitor, with an IC₅₀ of 7070 nM .

HY-163799

PRMT5-MTA-IN-1	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase *PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC₅₀* of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-172733S

PRMT5-MTA-IN-3-d3	Isotope-Labeled Compounds Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active *PRMT5-MTA* inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

HY-172733

PRMT5-MTA-IN-3	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-MTA-IN-3 inhibits cell proliferation in the MTAP-deficient colorectal cancer HCT - 116 cell line with an IC₅₀ value of 5 nM. PRMT5-MTA-IN-3 is promising for research of cancers, especially for MTAP-deficient tumors, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer .

HY-162989

PRMT5-MTA-IN-2	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-2 (compund 1) is a MTA co-inhibitor of *PRMT5* with IC₅₀ less than 1.5 nM .

Cat. No.	Product Name	Chemical Structure

HY-172733S

PRMT5-MTA-IN-3-d3
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active *PRMT5-MTA* inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

PRMT5-MTA-IN-3-d3

PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.